Migotanie przedsionków – praktyczne aspekty terapii przeciwzakrzepowej

• Authors: Mysiak Andrzej , Kaaz Konrad , Kobusiak-Prokopowicz Małgorzata
• Languages of publication: PL

Keywords

PL

migotanie przedsionków; leczenie przeciwzakrzepowe; nowe antykoagulanty

• Publisher: Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
• Journal: Family Medicine & Primary Care Review
• Year: 2013
• Issue: 3
• Pages: 471-473

Contributors

author

Mysiak Andrzej

author

Kaaz Konrad

author

Kobusiak-Prokopowicz Małgorzata

References

• Karppi J, Kurl S, Mäkikallio TH, et al. Low levels of plasma carotenoids are associated with an increased risk of atrial fibrillation.Eur J Epidemiol 2012; Dec 13. [Epub ahead of print].
• Kirchhof P, Auricchio A, Bax J, et al. Outcome parameters for trials in atrial fibrillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA ). Eur Heart J 2007; 28: 2803–2817.
• Go AS , Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA ) Study. JAMA 2001; 285:2370–2375.
• Stewart S, Hart CL, Hole DJ, et al. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86: 516–521.
• Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC ). Eur Heart J 2010; 31: 2369–2429.
• Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137: 263–272.
• Olesen JB, Fauchier L, Lane DA, et al. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 2012; 141: 147–153
• Friberg L, Benson L, Rosenqvist M, et al. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ 2012; 344: e3522.
• Connolly SJ, Eikelboom J, Joyner C, et al. AVERRO ES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806–817.
• Granger CB , Alexander JH, McMurray JJ, et al. ARISTOT LE Committees and Investigators. Apixaban vs. warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981–992.
• Patel MR, Mahaffey KW, Garg J, et al. ROC KET AF Investigators. Rivaroxaban vs. warfarin in nonvalvular atrial fibrillation.N Engl J Med 2011; 365: 883–891.
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361: 1139–1151.
• Seshasai SR , Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172: 209–216.
• Turakhia MP, Hoang DD, Xu X, et al. Differences and trends in stroke prevention anticoagulation in primary care vs cardiology specialty management of new atrial fibrillation: the Retrospective Evaluation and Assessment of Therapies in AF (TR EAT -AF)study. Am Heart J 2013; 165(1): 93–101
• Camm AJ, Lip GY, De Caterina R, et al. Wytyczne ESC dotyczące postępowania w migotaniu przedsionków na 2012 rok. Uaktualnienie wytycznych Europejskiego Towarzystwa Kardiologicznego (ESC ) dotyczących postępowania w migotaniu przedsionków z 2010 roku. Kardiol Pol 2012; 70(Supl. IV): 197–234.
• Camm AJ, Kirchhof P, Lip GY, et al. Wytyczne dotyczące postępowania u chorych z migotaniem przedsionków. Kardiol Pol 2010; 68(Supl. VII ): 487–566.
• Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363–2372.
• Huisman MV, Lip GY, Diener HC, et al. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012; 107: 838–847.
• Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011; 32: 2387–2394.
• Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran vs. warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation 2011; 123: 131–136.
• Corley SD, Epstein AE, DiMarco JP, et al. AFFIR M Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIR M) Study. Circulation 2004; 109: 1509–1513.
• Camm AJ, Lip GY, De Caterina R, et al. An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719–2747.
• Kim JS, She F, Jongnarangsin K, et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm 2012; Dec 10. [Epub ahead of print].